The AIDS epidemic - Considerations for the 21st century

New England Journal of Medicine

Volumn 341, Issue 14, 1999, Pages 1046-1050

  Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DRUG EFFICACY; HISTORY OF MEDICINE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; INFECTION PREVENTION; PRIORITY JOURNAL; VACCINATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANTI-HIV AGENTS; DISEASE OUTBREAKS; FEMALE; FORECASTING; HIV-1; HUMANS; MALE; WORLD HEALTH;

EID: 0033619146     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199909303411406     Document Type: Article

References (48)

1. Krause RM. Introduction to infectious diseases: stemming the tide. In: Krause RM, ed. Emerging infections. New York: Academic Press, 1998: 1-22.
2. History of influenza. In: Kilbourne ED. Influenza. New York: Plenum Medical Book, 1987:3-22.
3. Fauci AS. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science 1988;239:617-22.
4. Gao F, Bailes E, Robertson DL, et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 1999;397:436-41.
5. Hirsch VM, Olmsted RA, Murphey-Corb M, Purcell RH, Johnson PR. An African primate lentivirus (SIVsm) closely related to HIV-2. Nature 1989;339:389-92.
6. Weiss RA, Wrangham RW. From Pan to pandemic. Nature 1999;397: 385-6.
7. Quinn TC, Fauci AS. The AIDS epidemic: demographic aspects, population biology, and virus evolution. In: Krause RM, ed. Emerging infections. New York: Academic Press, 1998:327-63.
8. Kramer L. Reports from the holocaust: the story of an AIDS activist. London: Cassell, 1994.
9. Karon JM, Rosenberg PS, McQuillan G, Khare M, Gwinn M, Petersen LR. Prevalence of HIV infection in the United States, 1984 to 1992. JAMA 1996;276:126-31.
10. Sweeney PA, Fleming PL, Karon JM, Ward JW. Minimum estimate of the number of living HIV infected persons confidentially tested in the United States. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28 -October 1, 1997. Washington, D.C.: American Society for Microbiology, 1997: 245. abstract.
11. HIV/AIDS surveillance report. Vol. 10. No. 2. Atlanta: Centers for Disease Control and Prevention, 1998:1-43.
12. Rosenberg PS. Scope of the AIDS epidemic in the United States. Science 1995;270:1372-5.
13. Rosenberg PS, Biggar RJ, Goedert JJ. Declining age at HIV infection in the United States. N Engl J Med 1994;330:789-90.
14. AIDS epidemic update: December, 1998. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS), World Health Organization, 1998.
15. The world health report 1999: making a difference. Geneva: World Health Organization, 1999.
16. Removing obstacles to healthy development. Geneva: World Health Organization, 1999.
17. Department of Economic and Social Affairs of the United Nations Secretariat. The demographic impact of HIV/AIDS. New York: United Nations, 1999.
18. Hoyert DL, Kochanek KD, Murphy SL. Deaths: final data for 1997. Natl Vital Stat Rep 1999;47(19):1-104.
19. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998;352:1725-30.
20. Dore GJ, Brown T, Tarantola D, Kaldor JM. HIV and AIDS in the Asia-Pacific region: an epidemiological overview. AIDS 1998;12:Suppl B: S1-S10.
21. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
22. Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999;179:717-20.
23. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent anti-retroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 1998;280:1497-503.
24. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1998;47(RR-5):43-82. (See updates at http://www.hivatis.org.)
25. Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR Morb Mortal Wkly Rep 1998;47(RR-4):1-43. (See updates at http://www.hivatis.org.)
26. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep 1998;47(RR-2):1-30. (See updates at http://www.hivatis.org.)
27. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A 1998;95:8869-73.
28. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997;94:13193-7.
29. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir of HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-300.
30. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma vircmia. Science 1997;278:1291-5.
31. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999;353:2195-9.
32. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999;340:1614-22.
33. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999;340:1605-13.
34. Pomerantz RJ. Residual HIV-1 disease in the era of highly active antiretroviral therapy. N Engl J Med 1999;340:1672-4.
35. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5:512-7.
36. Chun TW, Engel D, Mizell SB, et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 1999;5:651-5.
37. Harrigan PR, Whaley M, Montaner JS. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 1999;13:F59-F62.
38. Cooper DA, Emery S. Latent reservoirs of HIV infection: flushing with IL-2? Nat Med 1999;5:611-2.
39. Coates TJ, Collins C. Preventing HIV infection. Sci Am 1998;279:96-7.
40. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
41. Mofenson LM. Short-course zidovudine for prevention of perinatal infection. Lancet 1999;353:766-7.
42. Saba J. The results of the PETRA intervention trial to prevent perinatal transmission in sub-Saharan Africa. Chicago: Foundation for Retrovirology and Human Health, 1999. (See http://www.retroconference.org/99/lect_symposia/sym_session8.htm.) (See NAPS document no. 05531 for 19 pages, c/o Microfiche Publications, 248 Hempstead Tpke., West Hempstead, NY 11552.)
43. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354;795-802.
44. Elias C, Coggins C. Female-controlled methods to prevent sexual transmission of HIV. AIDS 1996;10:Suppl 3:S43-S51.
45. Mann JM. Medicine and public health, ethics and human rights. Hastings Cent Rep 1997;27(3):6-13.
46. Folkers GK, Fauci AS. The role of US government agencies in vaccine research and development. Nat Med 1998;4:Suppl:491-4.
47. Evans TG, Keefer MC, Weinhold KJ, et al. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp 120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 1999;180:290-8.
48. Francis DP, Gregory T, McElrath MJ, et al. Advancing AIDSVAX to phase 3: safety, immunogenicity, and plans for phase 3. AIDS Res Hum Retroviruses 1998;14:Suppl 3:S325-S331.